 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity. (Pubmed Central) - Oct 1, 2024
We utilized SARS-CoV-2 spike ferritin nanoparticle (SpFN), and SARS-CoV-2 receptor binding domain ferritin nanoparticle (RFN) immunogens, in an equine model to elicit hyperimmune sera and evaluated its sarbecovirus neutralization and protection capacity...Purified equine polyclonal IgG provided protection against Omicron XBB.1.5 virus in the K18-hACE2 transgenic mouse model. These results suggest that SARS-CoV-2-based nanoparticle vaccines can rapidly produce a broad and protective sarbecovirus response in the equine model and that equine serum has therapeutic potential against emerging SARS-CoV-2 VoC and diverse sarbecoviruses, presenting a possible alternative or supplement to monoclonal antibody immunotherapies.
- || SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
P1 data, Journal: SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. (Pubmed Central) - Jun 8, 2024
P1
These results suggest that SARS-CoV-2-based nanoparticle vaccines can rapidly produce a broad and protective sarbecovirus response in the equine model and that equine serum has therapeutic potential against emerging SARS-CoV-2 VoC and diverse sarbecoviruses, presenting a possible alternative or supplement to monoclonal antibody immunotherapies. SpFN/ALFQ was well tolerated and elicited robust and durable binding antibody and neutralising antibody titres against a broad panel of SARS-CoV-2 variants and other sarbecoviruses.
- SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
First-in-Human Phase I Trial of an Adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_906;
Individuals vaccinated with SpFN/ALFQ mounted neutralizing antibody responses against multiple clade 1 sarbecoviruses. The results of this first-in-human clinical trial represents a platform upon which to build future sarbecovirus vaccine development.
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques. (Pubmed Central) - Jan 8, 2024
The results of this first-in-human clinical trial represents a platform upon which to build future sarbecovirus vaccine development. Here we describe the antibody response induced by the SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine candidate adjuvanted with the Army Liposomal Formulation including QS21 (ALFQ) in non-human primates...In particular, RBD mAb WRAIR-5001 binds to the conserved cryptic region with high affinity to sarbecovirus clades 1 and 2, including Omicron variants, while
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. (Pubmed Central) - Mar 19, 2023
These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow. The early engagement of S-2P specific naive B cells and high titer IgM antibodies shape the development of long-term neutralization breadth.
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. (Pubmed Central) - May 30, 2022
The strength of the immune response suggests that dose sparing through reduced or single dosing in primates may be possible with this vaccine. Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization.
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. (Pubmed Central) - Feb 25, 2022
Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization. [Figure: see text].
- ||||| SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Clinical: Can anyone tell us about the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research (WRAIR)? And how promising is it? (Twitter) - Dec 22, 2021
- ||||| SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Clinical: NEW—scientists at Walter Reed Army Institute of Research will soon announce that they have developed a vaccine that protects people from COVID-19 and all its variants, even #Omicron, called The ‘Spike Ferritin Nanoparticle COVID-19 vaccine’, or SpFN. 🧵 https://t.co/C140590sPj (Twitter) - Dec 21, 2021
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. (Pubmed Central) - Dec 20, 2021
Passive transfer of immunoglobulin G (IgG) purified from SpFN- or RFN-immunized mice protects K18-hACE2 transgenic mice from a lethal SARS-CoV-2 challenge. Furthermore, S-domain nanoparticle immunization elicits ACE2-blocking activity and ID neutralizing antibody titers >2,000 against SARS-CoV-1, highlighting the broad response elicited by these immunogens.
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Journal: SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. (Pubmed Central) - Dec 15, 2021
We assessed a SARS-CoV-2 spike-ferritin nanoparticle (SpFN) immunogen paired with two distinct adjuvants, Alhydrogel or Army Liposome Formulation containing QS-21 (ALFQ) for unique vaccine evoked immune signatures...The presence of this epitope in SARS-CoV, suggests that generation of cross-reactive T cells may be induced against other coronavirus strains. Our study reveals that a nanoparticle vaccine, combined with a potent adjuvant that effectively engages innate immune cells, enhances SARS-CoV-2-specific durable adaptive immune T cell responses.
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Preclinical, Journal: A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. (Pubmed Central) - Oct 31, 2021
Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.
- SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
[VIRTUAL] SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1505;
These observations highlight the importance of SARS-CoV-2 neutralizing antibody levels in providing protection against emerging SARS-like coronaviruses and provide a robust platform for pandemic preparedness. Structure-based design enables development of a SARS-CoV-2 nanoparticle immunogen.
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Enrollment closed, Enrollment change: SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults (clinicaltrials.gov) - Sep 14, 2021
P1, N=29, Active, not recruiting, Sponsor: U.S. Army Medical Research and Development Command
Structure-based design enables development of a SARS-CoV-2 nanoparticle immunogen. Recruiting --> Active, not recruiting | N=72 --> 29
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
Enrollment open: SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults (clinicaltrials.gov) - Apr 5, 2021
P1, N=72, Recruiting, Sponsor: U.S. Army Medical Research and Development Command
Recruiting --> Active, not recruiting | N=72 --> 29 Not yet recruiting --> Recruiting
- | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine / Walter Reed Army Institute of Research, USAMRIID
New P1 trial: SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults (clinicaltrials.gov) - Mar 4, 2021
P1, N=72, Not yet recruiting, Sponsor: U.S. Army Medical Research and Development Command
- |||| Coronavirus Vaccine / USAMRIID, Walter Reed Army Institute of Research
#CNN #CNNTownHall #COVID19Pandemic #Covid19usa #CoronaVirusUSA @CDCgov @USAMRIID @HHSGov @PeterHotez @SteveFDA @CDCDirector @NIHDirector @ScottGottliebMD @arobach @DrJAshton @CNN @AstraZeneca @GileadSciences @UniofOxford (Twitter) - May 1, 2020
- ||| Coronavirus Vaccine / USAMRIID, Walter Reed Army Institute of Research
Great article written by my former senior resident @WalterReedArmy @benstarnesmd "Letter from Seattle: Amid COVID-19 pandemic, time to act is long past due" https://t.co/kiz7N65Fnj (Twitter) - Mar 22, 2020
- |||| Coronavirus Vaccine / USAMRIID, Walter Reed Army Institute of Research
Clinical: EVALI has fever, cough, chills, hard to breath, diarrhea, and need ventilator for severe cases. Exactly the same as Covid-19. CDC shut down an army lab USAMRIID right before EVALI outbreak. And Wuhan held an army sport event which US participated before Wuhan's outbreak. (Twitter) - Mar 10, 2020